Glyburide Compared to Insulin for the Treatment of Gestational Diabetes Mellitus: A Cost Analysis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective To compare the costs associated with glyburide compared to insulin for the treatment of gestational diabetes unresponsive to dietary therapy. Study design A cost model was designed. The model excluded costs that were identical for both treatment arms, such as the cost of monitoring glucose control. Insulin treatment costs included average wholesale drug costs, wholesale delivery costs (syringes, alcohol pads), and costs of office staff educating patients. Glyburide costs were based on average wholesale drug costs. Downstream costs of potential inpatient evaluation for hypoglycemia were included in the model. Results In our baseline model, glyburide was significantly less costly than insulin for the treatment of gestational diabetes. The average cost saving per patient based on wholesale drug costs and hospital costs was US$165.84. Actual retail drug savings and hospital charge savings are potentially considerably greater. The strongest determinant of cost savings was medication cost. The model was less sensitive to the one-time costs of inpatient treatment and patient education. Conclusion Glyburide is less costly than insulin for the treatment of gestational diabetes. Cost models can be useful to physicians deciding between two equally efficacious medications, allowing them to incorporate information about their individual practice styles with a complex balance of cost implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with insulin, glyburide may be more convenient, is less expensive (184)”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [184]
Citations
Cites
1 retracted
ACOG Practice Bulletin No. 30: Gestational Diabetes
(2001) · Obstetrics & Gynecology · doi:10.1097/00006250-200109000-00037 · Cited by 301
RetractedA comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 8×
“The cost of glyburide failure necessitating subsequent insulin treatment was modeled based on a 5-week trial of glyburide as described in Langer et al. Patients switching to insulin incurred the educational costs of an insulin new start.”
BackgroundMethodInfluentialSchaefer-Graf, U. M., Buchanan, T. A., Xiang, A., Songster, G., Montoro, M., & Kjos, S. L. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(00)70217-1 · Cited by 270
Effects of in-utero exposure to oral hypoglycaemic drugs
Piacquadio, K. M., Hollingsworth, D. R., & Murphy, H. (1991) · The Lancet · doi:10.1016/0140-6736(91)91512-s · Cited by 139
American Diabetes Association (1998) · Diabetes Care · doi:10.2337/diacare.21.1.s60 · Cited by 114
Prolonged Symptomatic Neonatal Hypoglycemia Associated with Maternal Chlorpropamide Therapy
Zucker, P., & Simon, G. (1968) · Pediatrics · doi:10.1542/peds.42.5.824 · Cited by 80 · cited 1×
“Until recently, oral therapy with sulfonylurea drugs had been contraindicated due to concerns regarding teratogenicity(3,4) and the possibility of neonatal hypoglycemia.(5) However, a recent report by Langer et al.”
Background
Cited by
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
“Compared with insulin, glyburide may be more convenient, is less expensive (184), does not require intensive educational instruction at initiation of therapy, and is preferred by most patients (179, 183).”
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002848 · Cited by 251
Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome
Langer, O., Yogev, Y., Xenakis, E. M.-J., & Rosenn, B. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.07.011 · Cited by 140
Metadata
- Authors
- Goetzl, L., & Wilkins, I.
- Affiliations
- Baylor College of Medicine (US)
- ORCID
- Goetzl, Laura
- Venue
- Journal of Perinatology
- Published
- 2002-06-27
- Volume
- 22
- Issue
- 5
- Pages
- 403-406
- ISSN
- 0743-8346 (ISSN-L)
- 1476-5543
- OpenAlex
- W2061072286
- Cited by
- 54
- References
- 6
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 11 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Perinatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- gestational diabetes mellitus, glibenclamide, insulin, cost comparison, cost model, hypoglycemia, drug costs, patient education, hospital costs
- MeSH terms
- Costs and Cost Analysis, Female, Glyburide, Hospitalization, Humans, Hypoglycemic Agents, Insulin, Pregnancy, Texas, Diabetes, Gestational, Hospital Charges, Models, Economic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glyburide Compared to Insulin for the Treatment of Gestational Diabetes Mellitus: A Cost Analysis. https://app.cochat.ai/papers/10.1038/sj.jp.7210759
- The paper
- Goetzl, L., & Wilkins, I. (2002). Glyburide Compared to Insulin for the Treatment of Gestational Diabetes Mellitus: A Cost Analysis. Journal of Perinatology. https://doi.org/10.1038/sj.jp.7210759
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.